Ignite Creation Date:
2025-12-26 @ 11:47 AM
Ignite Modification Date:
2025-12-26 @ 11:47 AM
Study NCT ID:
NCT05758116
Status:
RECRUITING
Last Update Posted:
2024-11-26
First Post:
2023-02-17
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients
Sponsor:
Peking University Cancer Hospital & Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-07-07
Start Date Type:
ACTUAL
Primary Completion Date:
2025-07-07
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-07-07
Completion Date Type:
ESTIMATED
First Submit Date:
2023-02-17
First Submit QC Date:
None
Study First Post Date:
2023-03-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-22
Last Update Post Date:
2024-11-26
Last Update Post Date Type:
ACTUAL